Total Payments
$5,148
2024 Payments
$451.47
Companies
24
Transactions
315
Medicare Patients
2,249
Medicare Billing
$256,195
Payment Breakdown by Category
Food & Beverage$5,116 (99.4%)
Other$31.83 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,116 | 314 | 99.4% |
| Long term medical supply or device loan | $31.83 | 1 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,706 | 97 | $0 (2024) |
| Janssen Biotech, Inc. | $863.31 | 80 | $0 (2024) |
| PFIZER INC. | $540.54 | 32 | $0 (2024) |
| Gilead Sciences, Inc. | $499.60 | 26 | $0 (2023) |
| Merck Sharp & Dohme LLC | $212.40 | 13 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $172.75 | 11 | $0 (2022) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $140.48 | 9 | $0 (2022) |
| Valeant Pharmaceuticals North America LLC | $130.93 | 4 | $0 (2017) |
| Novo Nordisk Inc | $107.55 | 1 | $0 (2018) |
| Daiichi Sankyo Inc. | $95.14 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $451.47 | 22 | ABBVIE INC. ($260.90) |
| 2023 | $533.61 | 29 | ABBVIE INC. ($292.88) |
| 2022 | $885.32 | 60 | ABBVIE INC. ($293.76) |
| 2021 | $787.53 | 54 | AbbVie Inc. ($265.05) |
| 2020 | $153.92 | 9 | Janssen Biotech, Inc. ($90.91) |
| 2019 | $695.96 | 49 | Gilead Sciences, Inc. ($321.80) |
| 2018 | $556.61 | 29 | AbbVie, Inc. ($183.90) |
| 2017 | $1,083 | 63 | AbbVie, Inc. ($325.07) |
All Payment Transactions
315 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $21.34 | General |
| Category: VIROLOGY | ||||||
| 12/16/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $26.04 | General |
| Category: LIVER DISEASE | ||||||
| 11/25/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 11/21/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $14.20 | General |
| Category: VIROLOGY | ||||||
| 11/13/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $38.47 | General |
| Category: LIVER DISEASE | ||||||
| 10/30/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $16.01 | General |
| Category: VIROLOGY | ||||||
| 10/08/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: Immunology | ||||||
| 09/30/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $18.91 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 09/25/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $12.73 | General |
| Category: VIROLOGY | ||||||
| 09/11/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $27.59 | General |
| Category: LIVER DISEASE | ||||||
| 09/10/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ, HUMIRA | Food and Beverage | In-kind items and services | $27.86 | General |
| Category: IMMUNOLOGY | ||||||
| 05/28/2024 | Boston Scientific Corporation | CRE PRO (Device) | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: CRE_ENDO | ||||||
| 05/14/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $19.52 | General |
| Category: Immunology | ||||||
| 04/30/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ, HUMIRA | Food and Beverage | In-kind items and services | $16.23 | General |
| Category: IMMUNOLOGY | ||||||
| 04/26/2024 | ABBVIE INC. | HUMIRA (Biological), RINVOQ | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: IMMUNOLOGY | ||||||
| 04/23/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $23.12 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/20/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $16.52 | General |
| Category: IMMUNOLOGY | ||||||
| 03/14/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $2.67 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/29/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $31.45 | General |
| Category: VIROLOGY | ||||||
| 02/02/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: IMMUNOLOGY | ||||||
| 01/23/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $21.82 | General |
| Category: VIROLOGY | ||||||
| 01/11/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $23.48 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2023 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: VIROLOGY | ||||||
| 11/30/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $20.20 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2023 | ABBVIE INC. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: GASTROENTEROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 440 | 451 | $285,765 | $49,754 |
| 2022 | 14 | 579 | 609 | $321,460 | $63,783 |
| 2021 | 16 | 651 | 700 | $375,225 | $78,002 |
| 2020 | 11 | 579 | 621 | $309,968 | $64,656 |
Total Patients
2,249
Total Services
2,381
Medicare Billing
$256,195
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 134 | 134 | $137,350 | $26,897 | 19.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 75 | 75 | $48,375 | $4,417 | 9.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 50 | 55 | $10,175 | $3,070 | 30.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 49 | 49 | $42,875 | $2,960 | 6.9% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 16 | 16 | $12,000 | $2,710 | 22.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 38 | 39 | $10,530 | $2,591 | 24.6% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 26 | 26 | $10,530 | $2,403 | 22.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 18 | 18 | $4,320 | $1,798 | 41.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $6,970 | $1,573 | 22.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 22 | $2,640 | $1,336 | 50.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 137 | 137 | $140,425 | $26,856 | 19.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 101 | 102 | $65,790 | $6,830 | 10.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 60 | 70 | $18,900 | $6,197 | 32.8% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 30 | 30 | $22,500 | $5,297 | 23.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 71 | 74 | $13,690 | $4,677 | 34.2% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2022 | 34 | 34 | $13,770 | $3,498 | 25.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 21 | 21 | $8,610 | $2,175 | 25.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 31 | 31 | $8,370 | $1,858 | 22.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 15 | 15 | $3,600 | $1,559 | 43.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 26 | $3,120 | $1,427 | 45.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 19 | 19 | $16,625 | $1,091 | 6.6% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 14 | 14 | $2,100 | $1,085 | 51.6% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 15 | 21 | $1,785 | $633.26 | 35.5% |
| 76705 | Limited ultrasound scan of abdomen | Office | 2022 | 14 | 15 | $2,175 | $601.56 | 27.7% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 149 | 150 | $153,750 | $30,584 | 19.9% |
About Dr. Patrick Mcdevitt, D.O
Dr. Patrick Mcdevitt, D.O is a Gastroenterology healthcare provider based in Carlisle, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/08/2007. The National Provider Identifier (NPI) number assigned to this provider is 1245443860.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Mcdevitt, D.O has received a total of $5,148 in payments from pharmaceutical and medical device companies, with $451.47 received in 2024. These payments were reported across 315 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($5,116).
As a Medicare-enrolled provider, Mcdevitt has provided services to 2,249 Medicare beneficiaries, totaling 2,381 services with total Medicare billing of $256,195. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Carlisle, PA
- Active Since 05/08/2007
- Last Updated 01/09/2026
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1245443860
Products in Payments
- STELARA (Biological) $704.43
- MAVYRET (Drug) $328.80
- Humira (Biological) $294.96
- INFLECTRA (Biological) $264.09
- RINVOQ (Biological) $237.65
- XELJANZ (Drug) $237.58
- HUMIRA (Biological) $187.95
- Epclusa (Drug) $176.52
- XIFAXAN (Drug) $157.74
- LINZESS (Drug) $148.32
- DIFICID (Drug) $147.42
- REMICADE (Biological) $136.00
- Creon (Drug) $134.71
- Tresiba (Drug) $107.55
- SKYRIZI (Biological) $101.83
- UCERIS (Drug) $98.01
- INJECTAFER (Drug) $95.14
- ZEPOSIA (Drug) $95.02
- RESMETIROM (Drug) $92.10
- ZEPATIER (Drug) $64.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Carlisle
Robert Levy, D.o, D.O
Gastroenterology — Payments: $7,624
Gastroenterology $7,624
Tareq Yasin, Md, MD
Gastroenterology — Payments: $7,105
Gastroenterology $7,105
Jonathan Verrecchio, Do, DO
Gastroenterology — Payments: $4,327
Gastroenterology $4,327
Theodore Berk, M.d, M.D
Gastroenterology
Gastroenterology
Gregory Lewis, M.d, M.D
Gastroenterology
Gastroenterology